東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Reactive oxygen species = network ph...

Schmidt, Harald H. H. W.

Linked to FindBook

Google Book

Amazon

博客來

Reactive oxygen species = network pharmacology and therapeutic applications /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Reactive oxygen species/ edited by Harald H. H. W. Schmidt, Pietro Ghezzi, Antonio Cuadrado.
Reminder of title:	network pharmacology and therapeutic applications /
other author:	Schmidt, Harald H. H. W.
Published:	Cham :Springer International Publishing : : 2021.,
Description:	viii, 425 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	Active oxygen - Physiological effect. -
Online resource:	https://doi.org/10.1007/978-3-030-68510-2
ISBN:	9783030685102

Reactive oxygen species = network pharmacology and therapeutic applications /
Reactive oxygen speciesnetwork pharmacology and therapeutic applications /[electronic resource] :edited by Harald H. H. W. Schmidt, Pietro Ghezzi, Antonio Cuadrado. - Cham :Springer International Publishing :2021. - viii, 425 p. :ill., digital ;24 cm. - Handbook of experimental pharmacology,v.2640171-2004 ;. - Handbook of experimental pharmacology ;v.264..

Reactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term 'oxidative stress' is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology. Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.

ISBN: 9783030685102

Standard No.: 10.1007/978-3-030-68510-2doiSubjects--Topical Terms:

871917
Active oxygen
--Physiological effect.

LC Class. No.: RB170

Dewey Class. No.: 616.07

Reactive oxygen species = network pharmacology and therapeutic applications /
LDR:02327nmm a2200325 a 4500 001 2237878
003 DE-He213
005 20210419140232.0
006 m d
007 cr nn 008maaau
008 211111s2021 sz s 0 eng d
020 $a 9783030685102 $q (electronic bk.)
020 $a 9783030685096 $q (paper)
024 7 $a 10.1007/978-3-030-68510-2 $2 doi
035 $a 978-3-030-68510-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RB170
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 616.07 $2 23
090 $a RB170 $b .R281 2021
245 0 0 $a Reactive oxygen species $h [electronic resource] : $b network pharmacology and therapeutic applications / $c edited by Harald H. H. W. Schmidt, Pietro Ghezzi, Antonio Cuadrado.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a viii, 425 p. : $b ill., digital ; $c 24 cm.
490 1 $a Handbook of experimental pharmacology, $x 0171-2004 ; $v v.264
520 $a Reactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term 'oxidative stress' is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology. Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
650 0 $a Active oxygen $x Physiological effect. $3 871917
650 0 $a Oxidative stress. $3 899116
650 1 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Cardiology. $3 861477
650 2 4 $a Neurosciences. $3 588700
650 2 4 $a Medical Biochemistry. $3 892387
700 1 $a Schmidt, Harald H. H. W. $3 1001555
700 1 $a Ghezzi, Pietro. $3 3490487
700 1 $a Cuadrado, Antonio. $3 3490488
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Handbook of experimental pharmacology ; $v v.264. $3 3490489
856 4 0 $u https://doi.org/10.1007/978-3-030-68510-2
950 $a Biomedical and Life Sciences (SpringerNature-11642)